Eledon Pharmaceuticals, Inc.·4

Nov 22, 5:00 PM ET

Gros David-Alexandre C 4

4 · Eledon Pharmaceuticals, Inc. · Filed Nov 22, 2024

Insider Transaction Report

Form 4
Period: 2024-11-21
Gros David-Alexandre C
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (right to buy)

    2024-11-21+1,015,7431,015,743 total
    Exercise: $2.30Exp: 2033-05-01Common Stock (1,015,743 underlying)
Footnotes (1)
  • [F1]This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 1,015,743 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 380,904 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 634,839 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4